Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29740650 | 0.83 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CGPIK3CBF10 | |
| SCHEMBL20124865 | 0.83 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CGPIK3CBF10 | |
| SCHEMBL2940366 | 0.81 | MAP4K1 (0.50) | PIK3CDPIK3CAPIK3CGPIK3CBFAAH | |
| SCHEMBL10272402 | 0.81 | ALDH1A1 (0.52) | PIK3CDPIK3CAPIK3CGPIK3CBMGLL | |
| SCHEMBL13097259 | 0.81 | F10 (0.49) | PIK3CDPIK3CAPIK3CGPIK3CBF10 | |
| SCHEMBL20502398 | 0.81 | ALDH1A1 (0.48) | PIK3CDPIK3CAPIK3CGPIK3CBMGLL | |
| SCHEMBL15628319 | 0.80 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL28834548 | 0.80 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL198132 | 0.80 | PTGS2 (0.57) | F10PTGS2 | |
| SCHEMBL793560 | 0.79 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3CGPIK3CBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2770998-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8980916-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980916-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140322195-A1 | Factor IXA Inhibitors | MERCK SHARP & DOHME LLC | 2014-10-30 | — | — | US | disclosed |
| US-20140322195-A1 | Factor IXA Inhibitors | MERCK SHARP & DOHME LLC | 2014-10-30 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-10 | — | — | US | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025565-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-03 | — | — | WO | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322195-A1 | Factor IXA Inhibitors | F9, F12, F11 | PIK3CD 2212/4885PIK3CA 1220/4885PIK3CG 1478/4885 |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | PIK3CD 3641/4885PIK3CA 2290/4885PIK3CG 2893/4885 |
| US-20110059958-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | PIK3CD 3641/4885PIK3CA 2290/4885PIK3CG 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.